Enhance your confidence in interpreting Cerianna images with flexible, peer-led training designed for nuclear medicine physicians.

Cerianna is a molecular imaging diagnostic agent which reflects the presence of estrogen receptors and their potential ability to bind to estradiol. Its unique mechanism of action may help provide a clearer diagnosis for patients with ER+ recurrent or metastatic breast cancer.  

To support accurate interpretation, GE HealthCare offers expert-led reader training in two convenient formats—on-demand modules and live virtual sessions—so you can choose what works best for your schedule and learning style.

Choose your preferred training format 

In the form below choose between a convenient, on-demand option or live virtual training.

Register for Cerianna Reader Training

About Cerianna™
Cerianna PET reveals whole-body ER+ lesion status in patients with recurrent or metastatic breast cancer that may help guide clinical decisions.

INDICATIONS AND USAGE
CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer.

CONTRAINDICATIONS
None.

ADVERSE REACTIONS
In clinical trials evaluating the safety of CERIANNA in patients with breast cancer (n=1207), the following adverse reactions occurred at a rate < 1%: injection-site pain and dysgeusia.

For full Prescribing Information, click here.